Fierce Biotech BET inhibitor/PD-L1 cancer article

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Fierce Biotech BET inhibitor/PD-L1 cancer article

posted on Sep 15, 2016 10:56AM

BET inhibitor tamps down PD-L1 activity in ovarian cancer cells

Click about for Fierce Biotech article which also links to the scientific manuscript as well as this summary/commentary article from the Wistar Instutute (where the study was performed). This pre-clinical in vitro work was done with the old prototype PAN BET inhibitor JQ1, which does not seem to be a viable clinical candidate since it never made it to clinical trials.

Zenith has known about PAN BET inhibitors affecting PD-L1/PD1 biology for some time now. Nice to see another group publishing on this and re-assuring me that Zenith is a leader in the BET inhibitor field.